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Idylla EGFR Mutation Assay in NSCLCLung cancer is one of the four most common cancers in
Europe and the United States and is undoubtedly one of the
deadliest.1e3 Smoking is the primary risk factor for lung
cancer.4 Lung cancer is composed of two main histologic
subtypes: nonesmall-cell lung cancer (NSCLC) and small-
cell lung cancer, with NSCLC being the most frequently
diagnosed subtype (ie, 85%).
Prognosis is poor after advanced NSCLC diagnosis, with
the vast majority of patients not surviving, despite treat-
ment.5 An important improvement in the treatment of met-
astatic NSCLC was the development of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs),
such as afatinib, erlotinib, and gefitinib.6,7 Those TKIs
inhibit the catalytic activity of mutated EGFR, a member of
the tyrosine kinase family comprising several isoforms.8,9
Although TKIs improve overall and progression-free sur-
vival, and overall response in NSCLC, resistance to this
class of compounds usually develops within 9 to 12 months
after initiation of therapy.10
EGFR is the gene that is most frequently mutated in
NSCLC in the Asian population (ie, in approximately 50%
of the Asian patients) and often in the Western population
(ie, in approximately 10% of patients), especially in never
smokers.11 At baseline, exon 19 deletions and point mu-
tation L858R in exon 21 account for approximately 85% to
90% of all EGFR-activating mutations.12 Less prevalent
EGFR mutations, in particular G719A/C/S, T790M, S768I,
exon 20 insertions, and L861Q, constitute the remaining
10%.13 The presence of most of these EGFR mutations is
predictive for sensitivity to TKIs,14 leading to improved
progression-free survival but without demonstrable impact
on overall survival; they are accordingly referred to as
sensitizing or activating EGFR mutations.15,16 An exon 20
insertion, on the contrary, may predict resistance.17 Hence,
it is required by guidelines to determine the EGFR muta-
tional status in advanced NSCLC for activating or resis-
tance mutations before initiation of TKI therapy.18e21
Appearance of point mutation T790M in exon 20 of
EGFR is pivotal in the development of resistance to
TKIs10; and, therefore, T790M should be monitored at least
at disease progression. Third-generation TKIs, like osi-
mertinib, have been designed to target the T790M mutation
and are used for treatment of patients who have developed
this resistance mutation.18,22 Recently, osimertinib has also
been approved by the US Food and Drug Administration as
a first-line treatment for both sensitizing and T790M-
mutated tumors.23,24
Routinely, EGFR mutation analysis is performed on
tumor tissue acquired by surgery or biopsy.25 However,
tumor tissues are not always satisfactory accessible, and
repeated surgery or biopsy to assess treatment resistance is
often inappropriate. Moreover, surgery and biopsy might
cause clinical complications, with intrathoracic biopsies
having a complication rate of 17.1%.26 As a result, tissue
samples are often small and may have limited tumor
content.The Journal of Molecular Diagnostics - jmd.amjpathol.orgSeveral commercially available CE-IVD kits and in-
house assays, based on Sanger sequencing, pyrosequenc-
ing, next-generation sequencing (NGS), real-time PCR, or
mass spectrometry, have been developed to routinely assess
the mutational status of formalin-fixed, paraffin-embedded
(FFPE) NSCLC tissue samples.27,28 Each of these methods
has its sensitivity, specificity, level of automation and
multiplexing, turnaround time, cost, and requirement for
specialized equipment and trained staff.
The Idylla EGFR Mutation Assay (Biocartis, Mechelen,
Belgium), performed on the Idylla platform, detects 51
EGFR mutations in FFPE NSCLC tissue samples. Biocartis
has since launched a CE-marked IVD (Idylla EGFR Muta-
tion Test) intended to determine the tumor EGFR mutation
status of patients with metastatic NSCLC at diagnosis of
advanced disease and to facilitate treatment decisions within
a multidisciplinary team. The Idylla EGFR Mutation Test is
the only fully automated CE-IVD test detecting the muta-
tions in EGFR exons 18, 19, 20, and 21 that are considered
clinically relevant, according to current international
guidelines.18e21
In the current study, amulticenter evaluation (15 centers) of
the performance of the Idylla EGFR Mutation Assay on 449
archived FFPE tissue sections, originating from NSCLC le-
sions, in comparison with data retrospectively obtained with
routine reference methods on matched samples is described.
Materials and Methods
Multicenter Study Design
Archived clinical FFPE tissues of 449 NSCLC patients were
selected for this study. Samples were obtained from 15
clinical centers: BioPath Innovations S.A./BioMarker So-
lutions Limited (Athens, Greece; London, UK; n Z 28);
Klinikum Augsburg (Augsburg, Germany; n Z 29); Hos-
pital del Mar (Barcelona, Spain; n Z 30); Hospital Uni-
versitari de Bellvitge/Catalan Institute of Oncology
(Hospitalet, Spain; n Z 30); University of Coimbra
(Coimbra, Portugal; n Z 31); Medizinisches Versorgungs-
zentrum (MVZ) Zentrum für Pathologie und Zytodiagnostik
GmbH (ZPZ) Köln (Cologne, Germany; n Z 31); Rig-
shospitalet (Copenhagen, Denmark; n Z 30); Royal Corn-
wall Hospital (Cornwall, UK; n Z 29); Canberra Hospital
(Garran, ACT, Australia; n Z 33); Laboratoriemedicin
Gävle (Gävleborg, Sweden; n Z 28); University Clinic for
Respiratory and Allergic Diseases (Golnik, Slovenia;
n Z 30); Maastricht UMCþ (Maastricht, the Netherlands;
n Z 30); Humanitas Research Hospital (Milan, Italy;
n Z 30); Toulouse Cancer University Institute (IUCT)
Oncopole (Toulouse, France; n Z 30); and University
Hospital Zurich (Zurich, Switzerland; n Z 30). The use of
these patient samples was approved by the respective local
Ethics Committees and was in accordance with the Decla-
ration of Helsinki. Each of the 15 participating clinical
centers was asked to select and include at least one NSCLC1011
Evrard et alFFPE sample for each of the seven Idylla EGFR Mutation
Assay genotype calls indicated in Table 1.
In this study, Idylla EGFR Mutation Assay cartridges,
processed by the Idylla System, were used to analyze theTable 1 EGFR Mutations Detected by the Idylla EGFR Mutation Assay
Exon Mutation Protein change
18 G719A p.Gly719Ala
G719C p.Gly719Cys
G719S p.Gly719Ser
19 Del 9 p.Leu747_Ala750delinsPro
p.Leu747_Ala750delinsSer
p.Leu747_Glu749del
Del 12 p.Leu747_Thr751delinsPro
p.Leu747_Thr751delinsSer
Del 15 p.Glu746_Ala750del
p.Leu747_Thr751del
p.Glu746_Thr751delinsAla
p.Glu746_Thr751delinsIle
p.Glu746_Thr751delinsVal
p.Lys745_Ala750delinsThr
p.Glu746_Thr751delinsLeu
p.Glu746_Thr751delinsVal
p.Glu746_Thr751delinsAla
p.Glu746_Thr751delinsGln
p.Ile744_Ala750delinsValLys
Del 18 p.Leu747_Pro753delinsSer
p.Glu746_Ser752delinsVal
p.Leu747_Ser752del
p.Glu746_Thr751del
p.Leu747_Pro753delinsGln
p.Glu746_Ser752delinsAla
p.Glu746_Ser752delinsAsp
p.Glu746_Pro753delinsValSer
p.Glu746_Ser752delinsIle
p.Glu746_Ser752delinsVal
Del 21 p.Leu747_Pro753del
p.Glu746_Ser752del
Del 24 p.Ser752_Ile759del
20 T790M p.Thr790Met
S768I p.Ser768Ile
InsG p.Asp770_Asn771insGly
InsASV p.Val769_Asp770insAlaSerVal
InsSVD p.Asp770_Asn771insSerValAsp
InsH p.His773_Val774insHis
21 L858R p.Leu858Arg
L861Q p.Leu861Gln
1012EGFR mutational status of these archival FFPE tissue sec-
tions from human NSCLC tissue. Participating centers
received proper training to perform the Idylla EGFR Mu-
tation Assay before starting the study. The FFPE tissueNucleotide change Genotype call Idylla
c.2156G>C G719A/C/S
c.2155G>T
c.2154_2155delinsTT
c.2155G>A
c.2238_2248delinsGC Exon 19 deletion
c.2239_2248delinsC
c.2240_2248del
c.2239_2247del
c.2239_2251delinsC
c.2240_2251del
c.2235_2249del
c.2236_2250del
c.2239_2253del
c.2240_2254del
c.2238_2252del
c.2237_2251del
c.2235_2252delinsAAT
c.2237_2252delinsT
c.2234_2248del
c.2236_2253delinsCTA
c.2237_2253delinsTA
c.2235_2251delinsAG
c.2236_2253delinsCAA
c.2230_2249delinsGTCAA
c.2240_2257del
c.2237_2255delinsT
c.2239_2256del
c.2236_2253del
c.2239_2258delinsCA
c.2237_2254del
c.2238_2255del
c.2237_2257delinsTCT
c.2236_2255delinsAT
c.2236_2256delinsATC
c.2237_2256delinsTT
c.2237_2256delinsTC
c.2235_2255delinsGGT
c.2238_2258del
c.2236_2256del
c.2253_2276del
c.2369C>T T790M
c.2303G>T S768I
c.2310_2311insGGT Exon 20 insertion
c.2307_2308insGCCAGCGTG
c.2309_2310delinsCCAGCGTGGAT
c.2311_2312insGCGTGGACA
c.2319_2320insCAC
c.2573T>G L858R
c.2573_2574delinsGT
c.2573_2574delinsGA
c.2582T>A L861Q
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Figure 1 Idylla Explore version 2.5.1294.1 (Biocartis, Mechelen, Belgium) default display of a sample with an exon 19 mutation (deletion 15) present:
detail of PCR curves and cycle of quantification (Cq) values. Idylla Explore display of a sample with an exon 19 mutation present. A: Details of PCR curves and
Cq values; Cq values are available for the sample processing controls, EGFR Total, and the target for which a signal has been detected (default view); black PCR
curves represent the EGFR Total, and green PCR curve represents the EGFR exon 19 target [deletion 15 (Del 15)]. B: Detail of PCR curves (Idylla Explore default
view). The letters A to E in the image reflect the five PCR chambers in the Idylla cartridge.
Idylla EGFR Mutation Assay in NSCLCsections (mostly one, up to six) had a thickness of 5 or 10
mm and were sampled within the same FFPE block and
mostly consecutive to the sections used before to generate
the reference result with the routine method. Tumor content
and area of the specimen were determined on hematoxylin-
eosinestained slides by a pathologist and, if needed, mac-
rodissection was performed to achieve a neoplastic cell
content of at least 10%. The FFPE tissue sections were
placed directly into the Idylla cartridge following the assay
instructions of the manufacturer (Biocartis).
Artificial FFPE samples (ie, FFPE Reference Standards
from Horizon Discovery, Cambridge, UK) were included as
external controls: all 15 sites tested EGFR L858R and
T790M, both at a 20% allelic frequency.
Idylla EGFR Mutation Assay Description
The Biocartis Idylla EGFR Mutation Assay, performed on
the Idylla System, is an assay intended for the qualitative
detection of 51 different EGFR oncogene mutations: exon
18 (G719A/C/S), exon 19 (deletions), exon 20 mutations
(T790M, S768I, and insertions), and exon 21 (L858R andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgL861Q). The detected EGFR mutations and the corre-
sponding Idylla EGFR Mutation Assay genetic calls are
presented in Table 1. In this study, the Idylla EGFR
Investigational Use Only Assay has been used, as the CE-
IVDelabeled Idylla EGFR Mutation Test was not yet on the
market. The Idylla EGFR Mutation Assay has, in contrast to
the Idylla EGFR Mutation Test (IVD), no performance
claims.
The Idylla EGFR Mutation Assay uses FFPE tissue sec-
tions originating from NSCLC lesions, with a minimum
input of one FFPE section (5 mm thick) containing at least
10% of neoplastic cells. The time of completion from FFPE
tissue sample to test result (not including macrodissection, if
any) is approximately 2.5 hours, with <2 minutes hands-on
time. In the cartridge, the entire process from FFPE sample
to result, including fully integrated sample preparation,
liberation of nucleic acids, and real-time PCR amplification
and detection, is covered. Briefly, after insertion of the
FFPE tissue section into the cartridge, deparaffinization,
disruption of the tissue, and lysis of the cells are induced by
a combination of chemical reagents, enzymes, heat, and
high-intensity focused ultrasound. The resulting liberated1013
Table 2 Comparison between Results of the Idylla EGFRMutation Assay and Results of Routine ReferenceMethods (15 Sites, 449 NSCLC Samples)
Reference methods
G719A/C/S Ex19del T790M S768I Ex20ins L858R L861Q
G719A/C/S þ
S768I
Ex19del þ
T790M
Ex19del þ
L858R
Idylla G719A/C/S 5
Ex19del 87 1
T790M
S768I 2 1
Ex20ins 6
L858R 52 1
L861Q 7
G719A/C/S þ S768I 9
Ex19del þ T790M 1 18
Ex19del þ L861Q
L858R þ T790M
L858R þ S768I 1
L861Q þ T790M 1
G719A/C/S þ S768I
þ L861Q
No mut detected 6 2 1
Invalid/error 3z
Total 5 97 0 2 6 55 9 10 19 1
(table continues)
Routine reference methods: Ion Torrent AmpliSeq Colon and Lung Cancer Research Panel version 2 (Thermo Fisher Scientific), Oncomine panel (Thermo Fisher
Scientific), HaloPlex Cancer Research Panel (Agilent Technologies), in-houseedeveloped next-generation sequencing, therascreen EGFR Pyro Kit (Qiagen), in-
houseedeveloped pyrosequencing, cobas EGFR Mutation Test version 2 (Roche), therascreen EGFR RGQ PCR Kit version 1 or 2 (Qiagen), MassArray Lung Cancer
Panel (Diatech), and Sanger sequencing. Values in parentheses were not included in the data set used for concordance analysis.
*n Z 16 (Discordant by design).y
Exon 19 (7), exon 20 (4), and exon 21 (1).zn Z 6 (invalid/error).
Ex19del, exon 19 deletion; Ex20ins, exon 20 insertion; mut, mutation; NSCLC, nonesmall-cell lung cancer.
Evrard et alnucleic acids are then analyzed in five parallel multiplex
PCRs by means of highly selective target amplification
primers and using fluorescently labeled probes to detect
target sequences. To this end, the cartridge contains allele-
specific primers and probes and all necessary PCR reagents
present in a stable formulation. A conserved fragment in the
transmembrane region of the EGFR gene is amplified
simultaneously and serves as a sample processing control
(named EGFR Total) to check for adequate execution of the
complete process and as a measure for the amount of
amplifiable DNA in the sample.
The resulting fluorescence signals are analyzed in the
Idylla System by EGFR-specific software and translated into
genetic calls. To this end, the fluorescence signals are
evaluated for PCR curve validity; and for each valid curve, a
cycle of quantification value (Cq) is calculated. The pres-
ence of a mutant genotype is determined by calculating the
difference between the EGFR Total Cq and the Cq obtained
for the mutant signal(s) (ie, the DCq). A DCq value within a
predefined validated range defines a valid mutant signal
(mutation detected). Samples with a valid EGFR Total
signal but a DCq value outside the predefined range for a
mutant signal are reported as mutation negative (no1014mutation detected). In case no EGFR Total signal was
detected, no mutant result can be determined and the result
for that PCR is considered invalid. Invalid calls might be
due to insufficient DNA input, severe DNA fragmentation
(potentially caused by extended fixation time), the presence
of inhibitors in the sample, incorrect placement of a sample
in the cartridge, incorrect storage of the cartridge, use of a
cartridge that exceeded its in-use period after removal from
the pouch, or cartridge malfunctioning. For the genotype
calls that cover several mutations (eg, G719A/C/S, exon 19
deletion, and exon 20 insertion), the genotype call will be
reported as positive (mutation detected) if at least one valid
mutation signal is detected, regardless of the status (valid/
invalid) of the other mutations within the genotype call. For
the Idylla EGFR Mutation Assay to be invalid, all seven
genotypes must contain an invalid result. A result reporting
the presence, absence, or invalidity for each mutation or
mutation group in the EGFR gene in the analyzed sample is
displayed on the Idylla Console screen, as well as an
average of the Cq values of the EGFR Totals (present in
each of the five multiplex PCRs). If the Idylla report shows
a mix of invalid and valid genotype calls, the robustness for
the valid genotype call can be ensured. Each PCR chamberjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 2 (continued)
Reference methods
L858R þ
T790M
L858R þ
S768I
L858R þ
G719A/C/S
G719A/C/S þ
S768I þ
L861Q
Ex19del þ
T790M þ
other mut
Ex19del þ
L861Q þ
T790M
L858R þ
other mut
T790M þ
other mut
Other
mut
No mut
detected Invalid/error Total
1 6
88
1* 1
2 5
6
3 1 1 2* 60
1 8
9
1* 20
1 1
6 6
3 4
1
1 1
12*y 206 1z 228
1z 1z 5
9 4 1 1 1 1 2 1 12 211 2 449
Idylla EGFR Mutation Assay in NSCLCin the EGFR cartridge is individually validated for perfor-
mance by means of the sample processing control. If a
sample processing control signal of a PCR chamber is valid,
all results of the PCR chamber are considered valid, inde-
pendent of the performance of the other chambers.
The Idylla Explore application offers visualization of
PCR curves and the corresponding Cq values from the
Idylla EGFR Mutation Assay results (Figure 1). This is a
visualization tool and not intended to be used for data
interpretation.Reference Methods Used for Routine Analysis of EGFR
Mutations
The following reference methods were used for routine
analysis of the EGFR mutational status: NGS using the Ion
Torrent AmpliSeq Colon and Lung Cancer Research Panel
version 2 (Thermo Fisher Scientific, Waltham, MA; nZ 12
samples), the Oncomine Focus Assay (Thermo Fisher Sci-
entific; n Z 25), the HaloPlex Cancer Research Panel
(Agilent Technologies, Santa Clara, CA; n Z 20), or in-
houseedeveloped NGS (n Z 3); pyrosequencing using the
therascreen EGFR Pyro kit (Qiagen, Venlo, the Netherlands;
n Z 6) or in-houseedeveloped pyrosequencing (n Z 34);
PCR-based assays using the cobas EGFR Mutation Test
version 2 (Roche Molecular Systems, Pleasanton, CA;
nZ 130) or the therascreen EGFR RGQ PCR Kit version 1
or 2 (Qiagen; n Z 71); mass spectrometric methods usingThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthe MassArray Lung Cancer Panel (Diatech, Jesi, Italy;
n Z 30); and Sanger sequencing using in-house methods
(nZ 118). Commercial assays were performed according to
the manufacturer’s instructions. Analytical sensitivities for
the commercial assays can be found in the respective
manufacturer’s instructions. In-house methods were per-
formed by adopting different protocols and equipment at
each site.Methods Used in Further Analysis of Discordant
Samples
Digital droplet PCR (ddPCR) of DNA retrieved from the
Idylla EGFR Mutation Assay cartridge, of DNA used for the
reference method, and/or of FFPE tissue sections was per-
formed on a BioRad (Hercules, CA) QX100 system, ac-
cording to the manufacturer’s instructions.
Other methods used in further analysis were performed as
described above.Statistical Analysis
Agreement between Idylla and the comparator method was
evaluated on the basis of point estimates for overall, posi-
tive, and negative percentage diagnostic agreement together
with 95% one-sided Wilson score CIs.1015
Table 3 Other Mutations of EGFR Detected by Routine Reference Methods (Discordant by Design)
Samples Idylla results Routine reference method results Routine reference method used
11_03 ND Exon 19; c.2270A>G; p.L757R therascreen EGFR Pyro Kit
11_05 Exon 19; deletion Exon 19; deletion c.2235e2249; p.E746-A750del Sanger sequencing
Exon 20; T790M Exon 20, c.2369 C>T; p.T790M
ND Exon 20; c.2390G>C; p.C797S
11_07 ND Exon 20; c.2311_2319dupAACCCCTAC p.N771_H773dup;
c.2317C>T p.H773Y
Sanger sequencing
11_09 ND Exon 20; c.2335_2336delinsTT; p.G779F Sanger sequencing
07_04 ND Exon 19; deletion c.2236_2253delinsGTTAAT Sanger sequencing
14_05 ND Exon 19; c.2250_2276delinsCTC; p.T751_I759delinsS Sanger sequencing
14_18 ND Exon 19, c.2240_2264delinsCGAGAGA; p.L747_A755delinsSRD Sanger sequencing
14_25 ND Exon 19del; c.2252_2276delinsN; p.T751_I759delinsN Sanger sequencing
14_28 Exon 21; L858R Exon 21; c.2573T>G; p.L858R Sanger sequencing
ND Exon 18; c.2126A>C; p.E709A
10_15 ND Exon 20; c.2309_2317dup; p.D770_H773dup In-house NGS
13_28 ND Exon 20; c.2294_2295insGATGGC; p.V765_M766insMA cobas EGFR Mutation Test version 2
12_03 Exon 21; L858R Exon 21; c.2573T>G; p.L858R MassArray Lung Cancer Panel
ND Exon 18; p.E709G
12_23 ND Exon 21; p.L833V MassArray Lung Cancer Panel
ND Exon 21; p.H835L
03_05 ND Exon 19; c.2252_2276del25insA; p.T751_I759delinsN therascreen EGFR RGQ PCR Kit
03_10 Exon 21; T790M Exon 21; c.2369C>T; p.T790M therascreen EGFR RGQ PCR Kit
ND Exon 19; c.2252_2276del25insA; p.T751_I759delinsN
03_16 ND Exon 19; c.2246_2260del15; p.A750_K754del therascreen EGFR RGQ PCR Kit
ND, not detected.
Evrard et alResults
Verification with External Control Samples
At all 15 sites, the EGFR L858R and T790M (both at a 20%
allelic frequency) artificial FFPE samples (ie, FFPE Refer-
ence Standards from Horizon Discovery) were included as
external controls. The Idylla EGFR Mutation Assay, inde-
pendently performed at 15 sites, identified each of these two
mutations correctly; and, therefore, it can be concluded that
interlaboratory reproducibility of the external control sam-
ples was 100%.Performance of Idylla EGFR Mutation Assay on Clinical
Samples
Using the Idylla EGFR Mutation Assay, the EGFR muta-
tional status of archived clinical FFPE tissue sections,
originating from NSCLC lesions from 449 patients, was
determined at 15 centers (Supplemental Table S1). The
Idylla results were compared with the original results made
by routine reference methods (Materials and Methods).
Macrodissection was performed in 117 of the 449 cases to
increase the percentage of tumor area, as recommended in
the assay instructions for samples with low tumor
cellularity.
The Idylla EGFR Mutation Assay identified EGFR mu-
tations in 220 samples (Table 2). Deletions in exon 19 were
detected in 109 samples, 21 of which were associated with1016one other mutation detected by the Idylla EGFR Mutation
Assay. The L858R mutation was reported in 70 samples,
and in 10 of these samples L858R was associated with one
other mutation. A G719A/C/S mutation was detected in 16
samples, of which 10 were associated with one or two other
mutations. Eleven samples harbored an L861Q mutation,
and three of them were associated with one or two other
mutations. Among the 19 samples bearing an S768I muta-
tion, 14 were associated with one or two other mutations.
T790M was detected in 28 samples, of which 27 were
associated with one other EGFR variant. Finally, exon 20
insertions were found in six samples.
In 16 samples, routine reference methods identified rare
mutations of EGFR that were not detected by the Idylla
EGFR Mutation Assay (Tables 2 and 3). The negative Idylla
results could, however, be expected as the involved muta-
tions are not within the scope for which the Idylla EGFR
Mutation Assay has been designed. Therefore, these 16
samples were excluded from the analysis as discordant by
design.
An invalid or error call was reported in four cases with
the Idylla EGFR Mutation Assay (samples 02_06, 10_11,
08_13, and 08_17), in one sample with a routine refer-
ence method (sample 01_25, failing both the Ion Torrent
AmpliSeq Colon and Lung Cancer Research Panel
version 2 and the cobas EGFR Mutation Test version 2),
and in one sample with an invalid call for both the Idylla
EGFR Mutation Assay and the therascreen EGFR RGQ
PCR Kit, used as a routine reference methodjmd.amjpathol.org - The Journal of Molecular Diagnostics
Idylla EGFR Mutation Assay in NSCLC(sample 08_19). These six samples were excluded from
the data set.
As a result, the data set contained 427 (449  16  6)
samples for concordance analysis. Overall, in this first
assessment, without including the results of a third method
analysis, there was complete agreement between the Idylla
results and results of the routine reference methods in 402
cases of the 427 samples (overall concordance of 94.15%;
95% CI, 91.50%e96.00%).
Of the 427 cases, 25 discordant test results were observed
(Table 2). Of these 25 discordant samples, 13 were
considered as wild-type/mutant discordants (Table 4). For
the other 12 samples, there was a difference in number of
detected mutations; these are so called mutant/mutant þ 1
discordants (Table 5).
Overall, for 8 of the 25 discordant samples, the Idylla
EGFR Mutation Assay detected a mutation that was not
found by the routine reference method (negative percentage
agreement, 96.26%); and in 17 cases, the Idylla EGFR
Mutation Assay did not detect the reported mutation by the
routine reference method (positive percentage agreement,
92.02%).
Further Evaluation of the Discordant Results
Further analysis of the 25 discordant samples was per-
formed by analyzing new FFPE section material or, to
circumvent the low availability of FFPE material from
NSCLC lesions, by analyzing the DNA retrieved from the
Idylla cartridge or DNA as used for the reference method.
However, for eight samples (14_16, 01_11, 07_06, 14_11,
14_24, 01_18, 03_17, and 03_04) (Tables 4 and 5), the
DNA input was too low for additional analysis. As a
consequence, the test result for these samples was incon-
clusive; and the eight samples were therefore excluded from
the data set for the final concordance determination.
For samples 07_16 and 07_17 (Table 4), the exon 19
deletion was not detected on a new FFPE section with a
ddPCR technique. For sample 07_16, DNA was also
retrieved from the Idylla cartridge and analyzed by ddPCR;
and this test also did not result in the detection of the exon
19 deletion. However, the exon 19 deletion was detected by
another Idylla EGFR Mutation Assay on the DNA material
previously extracted and used for the reference method.
Hence, both samples were classified as inconclusive and
removed from the data set because it was suspected that the
inability to confirm the exon 19 deletion identified by the
routine reference method only was due to sample
heterogeneity.
As to sample 05_32, the therascreen EGFR RGQ PCR
Kit only identified mutation S768I, whereas the Idylla
EGFR Mutation Assay identified mutation G719A/C/S in
addition. As both results were clinically concordant, further
analysis was not performed on this sample. Therefore, this
sample was classified as inconclusive and removed from the
data set.The Journal of Molecular Diagnostics - jmd.amjpathol.orgIn summary, 11 of the 25 discordant samples were
removed from the data set. The next paragraphs describe in
detail the further analysis of the discordant samples.
Wild-Type/Mutant Discordant Samples
In 13 of 25 discordant samples, the Idylla EGFR Mutation
Assay identified mutations that were not detected by the
routine reference methods, or the other way around
(Table 4). Of these 13 samples, 9 were inconclusive (sam-
ples 14_16, 01_11, 07_06, 07_16, 07_17, 14_11, 14_24,
01_18, and 03_17), as explained in the previous paragraph.
Among the four remaining wild-type/mutant discordant
samples (01_08, 04_23, 14_12, and 10_08), the Idylla
EGFR Mutation Assay identified mutation L861Q in sample
04_23, whereas the cobas EGFR Mutation Test version 2
did not. The presence of L861Q was confirmed by ddPCR
on FFPE material as well as on DNA isolated from the
cartridge. The presence of mutation S768I in sample 01_08,
as detected by the Idylla EGFR Mutation Assay, was not
confirmed by ddPCR and NGS analysis of cartridge and of
FFPE material. The L861Q mutation, found earlier by
Sanger sequencing in sample 14_12, was confirmed by
ddPCR at an allelic frequency of 4%, which is below the
Idylla EGFR Mutation Assay limit of detection. The DNA
isolated from the cartridge of sample 10_08 was tested by
NGS; and the result confirmed the exon 19 deletion
c.2240_2257delTAAGAGAAGCAACATCTC, detected
before by pyrosequencing, at 57.74% allelic frequency. The
Idylla EGFR Mutation Assay did not identify this deletion
in this sample. The report of the NGS data revealed that a
second low-prevalence mutation was present in the sample
(ie, c.2264C>G). This mutation interferes with the primer/
probe annealing of the Idylla exon 19 deletion assay,
resulting in a substantial decreased sensitivity of the detec-
tion chemistry and the failure to detect the exon 19 deletion
with the Idylla EGFR Mutation Assay.
Mutant/Mutant þ 1 Discordant Samples
In 12 samples, an additional mutation was detected in either
the Idylla EGFR Mutation Assay or the routine reference
method; these samples are designated mutant/mutant þ 1
discordant samples (Table 5). Confirmation with ddPCR of
the three mutations detected with routine reference methods
in sample 03_04 was inconclusive, due to less than minimal
DNA input. Sample 05_32 was considered inconclusive as
no further analysis was performed. Both samples were,
therefore, excluded from the data set.
As to the remaining 10 mutant/mutant þ 1 discordant
samples, further analyses confirmed the results found by the
Idylla EGFR Mutation Assay in three samples (samples
09_12, 08_26, and 06_16). The Idylla EGFR Mutation
Assay identified mutation T790M in samples 09_12 and
08_26, whereas the cobas EGFR Mutation Test version 2
and the Qiagen therascreen EGFR RGQ PCR Kit did not,1017
Table 4 Wild-Type/Mutant Discordant Results between the Idylla EGFR Mutation Assay and Routine Reference Methods
Sample Baseline/progression
FFPE tissue
section, mm
FFPE tissue
sections put in
Idylla cartridge, n Tumor cells, % Tumor area, mm2
14_16 Progression 5 1 80 10
01_08 Baseline 5 1 10 0.04
01_11 Baseline 5 1 30 100
04_23 Baseline 5 2 50 18
07_06 Baseline 10 1 60 90
07_16 Baseline 10 1 80 30
07_17 Baseline 10 1 75 27
14_11 Baseline 10 1 10 5
14_12 Baseline 5 1 50 15
14_24 Baseline 5 1 >50 40
10_08 Baseline 5 2 >50 4
01_18 Baseline 5 1 85 100
03_17 Baseline 10 1 40 1
(table continues)
*Sanger sequencing.y
Digital droplet PCR.zcobas EGFR Mutation Test version 2 (Roche).
xIon Torrent AmpliSeq Colon and Lung Cancer Research Panel version 2 (Thermo Fisher Scientific).
{NGS Oncomine panel (Thermo Fisher Scientific).
ǁIn-house pyrosequencing.
**In-house next-generation sequencing.
yytherascreen EGFR RGQ PCR Kit (Qiagen).
d, To be excluded from data set; C, concordant; D, discordant; Ex19del, exon 19 deletion; FFPE, formalin fixed, paraffin embedded; LOD, limit of detection;
WT, wild type.
Evrard et alrespectively. ddPCR analysis on DNA from the cartridge
confirmed the presence of T790M at a low allelic frequency
(2.4% in sample 09_12 and 0.5% in sample 08_26). The
exon 19 deletion, reported by the cobas EGFR Mutation
Test version 2 in sample 06_16, was not confirmed by
ddPCR. Therefore, the Idylla EGFR Mutation Assay result
for the latter sample was classified as concordant.
In seven remaining samples, the results of the third
method used (ddPCR analysis) were not concordant with the
results obtained with the Idylla EGFR Mutation Assay; and
these samples were, thus, considered discordant. The S768I
mutation in sample 04_20, which was only detected by the
Idylla EGFR Mutation Assay and not by the cobas EGFR
Mutation Test version 2, was not confirmed by ddPCR on
DNA material from the cartridge or by ddPCR analysis of
FFPE material, but the latter was hindered by low DNA
content. In sample 13_08, the Idylla EGFR Mutation Assay
could not identify the mutation G719A/C/S, detected by the
cobas EGFR Mutation Test version 2. Using ddPCR,
G719S, at an allelic frequency of 0.15%, was detected on
DNA retrieved from the Idylla cartridge, whereas in FFPE
material, the same mutation was found at 0.25%. The
T790M mutation in sample 07_21, determined before by
Sanger sequencing only, was confirmed by ddPCR analysis
on a new FFPE tissue section. The allelic frequency was
0.5%. As Sanger sequencing needs at least 10% to 15%
mutated DNA to be detected, sample heterogeneity might
have contributed to this discordance. In samples 13_27 and101813_30, the T790M mutations, identified by the cobas EGFR
Mutation Test version 2 but not by the Idylla EGFR Mu-
tation Assay, were confirmed by ddPCR analysis, showing
the presence of T790M in both samples at allelic fre-
quencies (approximately 1% to 2%). The presence of mu-
tation T790M, found in sample 12_09 when using the
MassArray Lung Cancer Panel and not with the Idylla
EGFR Mutation Assay, was confirmed by ddPCR at 2.59%
allelic frequency in FFPE material and in DNA from the
cartridge. A ddPCR analysis of sample 03_09 on DNA
derived from the Idylla cartridge was inconclusive because
of insufficient material, although ddPCR on FFPE material
found an S768I mutation at 30% allelic frequency. Unlike
the earlier Sanger sequencing and therascreen EGFR RGQ
PCR Kit results, the original Idylla EGFR Mutation Assay
did not find this mutation. Considering the high allelic fre-
quency of the mutation, a retest of the Idylla EGFR Muta-
tion Assay on FFPE material was performed; and the S768I
was correctly reported, which could indicate sample
heterogeneity.
Performance of Idylla EGFR Mutation Assay
Using the results of the further analysis, as outlined above,
11 samples were removed from the data set of 427 samples
(samples 14_16, 01_11, 07_06, 07_16, 07_17, 14_11,
14_24, 01_18, 03_17, 05_32, and 03_04), bringing the total
number of samples down to 416. As well, of the remainingjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 4 (continued)
Macrodissection Idylla Routine reference method Further analysis
Conclusion based on
further analysis
No G719A/C/S No mutation detected* Inconclusivey d
No S768I No mutation detectedzx WTyx D
No S768I No mutation detectedx Inconclusiveyx d
No L861Q No mutation detectedz L861Qy C
Yes No mutation detected Ex19del* Inconclusivey d
Yes No mutation detected Ex19del{ Inconclusivey d
Yes No mutation detected Ex19del{ Inconclusivey d
No No mutation detected L858R* Inconclusivey d
No No mutation detected L861Q* 4% L861Qy D, L861Q<LOD
No No mutation detected L858R* Inconclusivey d
Yes No mutation detected Ex19delzǁ Ex19dely** D
No No mutation detected Ex19delz Inconclusiveyx d
No No mutation detected Ex19del*yy Inconclusivey d
Idylla EGFR Mutation Assay in NSCLC14 discordant samples, four (samples 06_16, 09_12, 04_23,
and 08_26) were reclassified as concordant, reducing the
total number of discordant samples to 10 (Tables 4 and 5).
Taking into account the decreased number of samples in the
data set and the increased number of concordant samples,
the findings of the Idylla EGFR Mutation Assay were in
agreement with the confirmed reference method results in
406 of 416 samples. Consequently, the overall concordance
with routine reference methods, including further analysis,
was found to be 97.59% (95% CI, 95.63%e98.69%), with a
negative percentage agreement of 96.26% (95% CI,
92.80%e98.09%) and a positive percentage agreement of
99.01% (95% CI, 96.46%e99.73%).Influence of Tissue Size on Idylla EGFR Mutation Assay
Result
The amount of tissue needed to enable a valid Idylla EGFR
Mutation Assay is small. For example, a tissue surface area
of 0.43 mm2 (sample 09_09) still gave a valid result that
was concordant with the earlier result of the routine refer-
ence method. There was neither a relationship between the
total tissue surface area and the validity of the Idylla EGFR
Mutation Assay nor between the total tissue surface area and
the concordance of the Idylla result with the routine refer-
ence method result (Table 6). This hypothesis was statisti-
cally confirmed using a c2 statistic: P value for validity of
0.63 and P value for concordance of 0.11.Discussion
The detection of EGFR mutations in NSCLC, either acti-
vating mutations in newly diagnosed NSCLC patient orThe Journal of Molecular Diagnostics - jmd.amjpathol.orgresistance mutations after first-generation EGFR TKI treat-
ment, is relevant because the latest guidelines by the Na-
tional Comprehensive Cancer Network and the European
Society for Medical Oncology recommend EGFR TKIs as
first-line therapy for patients with advanced NSCLC
harboring activating EGFR mutations.18e21
Numerous methods are available for the detection of
EGFR mutations, which necessitate many steps (deparaffi-
nization, DNA extraction, PCR amplification, and result
interpretation) in a specific infrastructure with expert staff to
perform analyses and interpret the results; they usually take
more than a day from sample to result. Moreover, the cur-
rent routine methods used for the detection of EGFR mu-
tations are often performed batch wise, with several samples
simultaneously, to be as cost effective as possible. This will
inevitably delay turnaround time from sample reception to
final result. The Idylla EGFR Mutation Assay, however,
requires minimal infrastructural measures and is designed to
run on a patient-per-patient base, which reduces turnaround
time dramatically. It could, therefore, be useful to answer
urgent requests.29,30
The current study compared the Idylla EGFR Mutation
Assay results with the original results obtained by routine
reference methods for the detection of EGFR mutations in
FFPE tissue samples. Each of the 15 participating clinical
centers included at least one NSCLC FFPE sample for each
of the seven Idylla EGFR Mutation Assay genotype calls
indicated in Table 1. Therein, the mutation rates obtained in
this study are not representative for the incidence of EGFR
mutations in the general NSCLC patient population.
In total, 449 NSCLC FFPE samples were selected and
tested. Samples that were discordant by design (nZ 16) or
obtained an invalid test result (nZ 6) with either the routine
method or the Idylla EGFR Mutation Assay were excluded.1019
Table 5 Mutant/Mutant þ 1 Discordant Results between the Idylla EGFR Mutation Assay and Routine Reference Methods
Sample Baseline/progression
FFPE tissue
section, mm
FFPE tissue
sections put in
Idylla cartridge, n Tumor cells, % Tumor area, mm2
09_12 Progression 5 1 30 3.19
04_20 Baseline 5 1 20 12
08_26 Baseline 5 5 >10 25
05_32 NA 5 1e4 60 w15
06_16 Baseline 10 6 15 4
07_21 Baseline 10 1 50 50
13_08 Baseline 5 1 50 100
13_27 Progression 5 2 20 200
13_30 Progression 5 2 30 15
12_09 NA 5 1 >50 100
03_04 Progression 10 1 75 2
03_09 Baseline 10 1 50 2
(table continues)
*cobas EGFR Mutation Test version 2 (Roche).y
Digital droplet PCR.ztherascreen EGFR RGQ PCR Kit (Qiagen).
xIdylla EGFR Mutation Assay retest.
{MassArray Lung Cancer Panel (Diatech).
kSanger sequencing.
d, To be excluded from data set; C, concordant; D, discordant; Ex19del, exon 19 deletion; FFPE, formalin fixed, paraffin embedded; Inconcl, inconclusive;
LOD, limit of detection; NA, information not available; ND, not determined.
Evrard et alThe fact that the mutants identified by the reference method
but classified as discordant by design have not been eval-
uated is a limitation of the Idylla EGFR Mutation Assay
because these mutants are rarely observed in large cohorts of
NSCLC and not of clinical importance.31e33
As a result, the final data set contained 427 samples for
concordant analysis. Discordance between results of the
Idylla EGFR Mutation Assay and routine reference methods
was observed for 25 of these 427 samples. The overall
concordance between the Idylla EGFR Mutation Assay and
the routine reference methods, before third method analysis,
was 94.14% (95% CI, 91.50%e96.00%). Further evaluation
of the discordant results obtained revealed a final overall
concordance of 97.59% (95% CI, 95.63%e98.69%). The 25
discordant results were investigated in depth and described
fully in the Results section. Some of the discordant results
can be explained by the low allelic frequencies of the pre-
sent mutations, which were below the limit of detection of
the assays. The discordances were divided into 13 wild-
type/mutant discordant samples (ie, the Idylla EGFR Mu-
tation Assay identified mutations not detected by the routine
reference methods or the other way around) and 12 mutant/
mutant þ 1 discordant samples (ie, the Idylla EGFR Mu-
tation Assay detected an additional mutation compared with
the routine reference method or the other way around).
The further discordant analyses were troubled (11 sam-
ples needed to be excluded) by two well-known root causes:
the low availability of FFPE material from NSCLC lesions
and tumor/sample heterogeneity. It is generally accepted
that tissue samples obtained from NSCLC patients are1020mostly small biopsies obtained by endoscopy or by image-
guided transthoracic core-needle biopsy.34 After histologic
analysis, which consumes numerous sections, and molecular
biology analyses performed with the routine reference
method used in the laboratory, usually only a small amount
of tissue sample material remains. Also, in this study, in
eight discordant cases, the FFPE materials remaining were
not sufficient to obtain results from further analysis with
additional methods and, thus, unfortunately these samples
needed to be excluded from the final concordance data set as
inconclusive. Second, tumor sample heterogeneity is an
issue in comparative studies.35,36 Sample heterogeneity was
a possible issue in two cases where the Idylla EGFR Mu-
tation Assay did not detect the exon 19 deletion detected
with the routine reference method; using a sensitive tech-
nique (ddPCR), detection of this mutation in DNA retrieved
from the cartridge (performed for one of the two samples)
and on a new FFPE section was also unsuccessful; however,
the Idylla EGFR Mutation Assay was able to detect the
mutation on the DNA material previously extracted and
used for the reference method. These two inconclusive
samples were, therefore, also removed from the final
concordance data set. Finally, one sample was considered
inconclusive as no further analysis was performed.
The final overall concordance between the Idylla EGFR
Mutation Assay and the confirmed reference routine test
results was, therefore, found to be 97.59% (95% CI,
95.63%e98.69%), with a negative percentage agreement of
96.26% (95% CI, 92.80%e98.09%) and a positive per-
centage agreement of 99.01% (95% CI, 96.46%e99.73%),jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 5 (continued)
Macrodissection Idylla Routine reference method Further analysis
Conclusion based on
further analysis
No Ex19del þ T790M Ex19del* Ex19del þ 2.4% T790My C, T790M<LOD
No L858R þ S768I L858R* L858Ry D
No L861Q þ T790M L861Qz L861Q þ 0.5% T790My C, T790M<LOD
Yes S768I þ G719A/C/S S768Ix ND d
No L858R L858R þ Ex19del* L858Ry C
Yes L858R L858R þ T790Mx L858R þ 0.5% T790My D, T790M<LOD
No L858R L858R þ G719A/C/S* L858R þ 0.15% G719 Sv D, G719S<LOD
No L858R L858R þ T790M* L858R þ 1e2% T790My D, T790M<LOD
No L858R L858R þ T790M* L858R þ 1.26% T790My D, T790M<LOD
No Ex19del Ex19del þ T790M{ ex19del þ 2,59% T790My D, T790M<LOD
Yes ex19del þ L861Q ex19del þ L861Q þ T790Mzk Inconcly d
No L858R L858R þ S768Izk L858R þ S768Ix D
Idylla EGFR Mutation Assay in NSCLCdemonstrating the good performance of the rapid Idylla
EGFR Mutation Assay.
Four discordant samples were reclassified as concordant
because third method analyses with either ddPCR or NGS
confirmed the mutations identified with the Idylla EGFR
Mutation Assay but not with the routine reference method.
Six other discordant samples exhibited L861Q, G719S, or
T790M mutations, according to the reference results. Third
method analysis revealed that the observed mutant allelic
frequencies were low (<5%), which can explain why the
Idylla EGFR Mutation Assay was not able to detect the
mutants at the given sample input; also, sample heteroge-
neity might have played a role.
For baseline testing at diagnosis of metastatic NSCLC,
the presence or absence of additional sensitizing mutations
does not influence therapy guidance. Of the 10 analytically
discordant samples, four baseline samples could, therefore,
be considered clinically concordant. On the contrary, for
samples tested at progression, the presence or absence of an
additional sensitizing mutation or of the T790M resistance
mutation can change therapy guidance.18 Two of the
analytically discordant samples taken at progression had a
discordant result at the level of the T790M mutation and
should, therefore, be considered clinically discordant. The
remaining four analytically discordant samples were also
considered clinically discordant because for two of them
(samples 14_12 and 12_09) the baseline/progression status
was unknown, and the two other samples (samples 01_08
and 10_08) were wild-type/mutant discordant samples.
Concerning the T790M mutant, it can be concluded that the
Idylla EGFR Mutation Assay missed the detection of low
mutant allelic frequency T790M (ie, <5%). Deamination in
FFPE samples is known to cause baseline noise in NGS
data.37 T790M is a target that is affected by deamination
and, therefore, entails the risk of false-positive calls due toThe Journal of Molecular Diagnostics - jmd.amjpathol.orgdeamination issues. In the Idylla EGFR Mutation Assay, the
sensitivity for T790M is, therefore, by design limited to
detect a mutant allelic frequency of 5% to reduce this risk.
As discussed in the previous paragraph, several factors
contribute to the fact that frequently only a small amount of
tissue sample remains to perform a molecular analysis to get
a conclusive result. Fortunately, the Idylla EGFR Mutation
Assay only needs a small amount of FFPE tissue sample.
Even with <10 mm2 of tissue area, the Idylla EGFR Mu-
tation Assay gave a valid result in 99.0% of the cases.
Recently, also, De Luca et al38 showed that 80% of the
samples that failed on NGS could be successfully tested
with the Idylla EGFR Mutation Test. Furthermore, in the
current study, it was shown that the percentage of valid
results was not related to the sample size. In the same
manner, there was no relationship between the size of the
tissue area and the concordance of the Idylla EGFR Muta-
tion Assay result with the routine reference method result,
which was comprised between 91.9% and 100.0%.
Taken together, the results of this comparative study
confirm the high sensitivity and specificity of the Idylla
EGFR Mutation Assay and its ability to provide valid and
concordant results starting from small tissue samples.
However, as counterargument, it can be challenged that for
samples of which not sufficient material could be recovered
for third method analysis, and which were in this study
classified as inconclusive, the Idylla EGFR Mutation Assay
was not able to detect a mutation, whereas the routine
method did. As also mentioned in the instructions for use of
the Idylla EGFR Mutation Assay, when a no mutation
detected result for all seven EGFR genotypes has been ob-
tained, the presence of a mutation in the seven EGFR ge-
notypes might not be excluded because the result is
dependent on the integrity of the specimen DNA, the per-
centage of mutant alleles present in the specimen, the1021
Table 6 Influence of Tissue Size on Validity of the Idylla EGFR Mutation Assay and Concordance with the Reference Method Result
Total tissue area, mm2 Valid, n/total (%) Concordant, excluding invalids, n/total (%)
<10 97/98 (98.98) 90/97 (92.78)
10 and <25 74/74 (100.00) 68/74 (91.89)
25 and <300 234/238 (98.32) 227/234 (97.01)
300 23/23 (100.00) 23/23 (100.00)
For five samples, the sample size was not recorded; samples that were discordant by design (n Z 16) are not included in this table. The exact number of
sections put in the cartridge was only recorded for 403 samples.
Evrard et alabsence of inhibiting substances, and the presence of suf-
ficiently amplifiable DNA. The average Cq of the EGFR
control, depicted on the report, gives an indication of the
quantity of amplifiable DNA present in the sample and is
linked to the analytical sensitivity. Thus, it can be concluded
that when insufficient amplifiable DNA is present in the
cartridge, it will affect the analytical sensitivity of the test
and logically the risk for a false-negative result might be
higher.
Although the Idylla EGFR Mutation Assay is not inten-
ded to detect all possible EGFR mutations or to quantify
allelic frequency, this multicenter performance study dem-
onstrates that the test can currently detect all the most
prevalent and clinically relevant EGFR mutations. A limi-
tation of the mutation coverage can be that the EGFR
C797S mutation is not included in the current Idylla EGFR
Mutation Assay. This mutation is reported to be a mecha-
nism of resistance to the third-generation inhibitors targeting
T790M. Fourth-generation EGFR TKIs, targeting the
C797S mutation, are not yet available. Nevertheless, other
molecular techniques could be used to either quantify the
EGFR mutation detected, if necessary, or to detect other
mutations of EGFR or to simultaneously detect the mutation
status of other potentially relevant tumor biomarkers.
Finally, although not included as outcome in this study
design, an important advantage of the rapid Idylla EGFR
Mutation Assay is the rapid turnaround time. Because the
detection of the EGFR mutational status could be pressing
for patients in a critical condition necessitating
urgent medical treatment, the Idylla EGFR Mutation Assay,
with its short turnaround time and low infrastructural re-
quirements, can be considered as a useful technology in
pathology laboratories. At present, Idylla EGFR has been
validated as a CE-marked IVD product. An overall per-
centage agreement of 95.9% (95% CI, 91.8%e100%) be-
tween the Idylla EGFR Mutation Test and the reference test
has been obtained; and the product is able to detect allelic
frequencies at 5% for mutations in exons 19, 20, and 21 of
the EGFR oncogene and 10% for mutations in exon 18 of
the EGFR oncogene.Conclusion
The current multicenter comparative study showed, with the
help of a large sample set, that the Idylla EGFR Mutation1022Assay is a sensitive and highly reliable test to detect the
most common and clinically relevant EGFR mutations in
FFPE tumor tissue, to quickly support the further assess-
ment by the tumor review board along with other genomic,
pathologic, and clinical data.Acknowledgments
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